What is Zacks Research’s Forecast for CME Group Q4 Earnings?

CME Group Inc. (NASDAQ:CME) – Investment analysts at Zacks Research increased their Q4 2024 earnings estimates for shares of CME Group in a note issued to investors on Wednesday, November 13th. Zacks Research analyst T. De now expects that the financial services provider will post earnings per share of $2.47 for the quarter, up from their previous forecast of $2.31. The consensus estimate for CME Group’s current full-year earnings is $10.23 per share. Zacks Research also issued estimates for CME Group’s Q1 2025 earnings at $2.57 EPS, Q2 2025 earnings at $2.50 EPS, Q3 2025 earnings at $2.57 EPS, FY2025 earnings at $10.19 EPS, Q1 2026 earnings at $2.75 EPS, Q2 2026 earnings at $2.71 EPS, Q3 2026 earnings at $2.44 EPS and FY2026 earnings at $10.62 EPS.

CME Group (NASDAQ:CME) last posted its quarterly earnings results on Wednesday, October 23rd. The financial services provider reported $2.68 EPS for the quarter, beating analysts’ consensus estimates of $2.65 by $0.03. The business had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.59 billion. CME Group had a return on equity of 13.39% and a net margin of 57.34%. The business’s quarterly revenue was up 18.4% on a year-over-year basis. During the same period last year, the firm earned $2.25 earnings per share.

A number of other brokerages have also weighed in on CME. Redburn Atlantic lowered shares of CME Group from a “buy” rating to a “neutral” rating and set a $244.00 target price for the company. in a research report on Tuesday, October 8th. Keefe, Bruyette & Woods lifted their target price on CME Group from $212.00 to $213.00 and gave the stock a “market perform” rating in a report on Thursday, July 25th. Morgan Stanley raised their price target on CME Group from $210.00 to $233.00 and gave the company an “equal weight” rating in a report on Thursday, October 17th. Piper Sandler upped their price objective on CME Group from $240.00 to $250.00 and gave the stock an “overweight” rating in a report on Monday, October 28th. Finally, Bank of America raised their target price on shares of CME Group from $177.00 to $180.00 and gave the company an “underperform” rating in a report on Thursday, October 3rd. Four equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, CME Group has an average rating of “Hold” and an average target price of $224.47.

CME Group Stock Up 0.8 %

NASDAQ CME opened at $225.28 on Friday. CME Group has a 12 month low of $190.70 and a 12 month high of $230.36. The company has a current ratio of 1.02, a quick ratio of 1.02 and a debt-to-equity ratio of 0.09. The stock has a market cap of $81.12 billion, a PE ratio of 23.66, a P/E/G ratio of 5.26 and a beta of 0.55. The stock’s 50 day moving average is $222.52 and its 200 day moving average is $210.26.

Hedge Funds Weigh In On CME Group

Hedge funds and other institutional investors have recently made changes to their positions in the company. Truvestments Capital LLC bought a new position in CME Group in the third quarter worth approximately $26,000. Dunhill Financial LLC boosted its position in CME Group by 188.4% during the third quarter. Dunhill Financial LLC now owns 124 shares of the financial services provider’s stock valued at $27,000 after purchasing an additional 81 shares in the last quarter. Y.D. More Investments Ltd purchased a new position in CME Group in the second quarter valued at about $36,000. McClarren Financial Advisors Inc. raised its holdings in CME Group by 66.1% in the second quarter. McClarren Financial Advisors Inc. now owns 196 shares of the financial services provider’s stock worth $39,000 after purchasing an additional 78 shares in the last quarter. Finally, Asset Dedication LLC lifted its position in shares of CME Group by 515.2% during the second quarter. Asset Dedication LLC now owns 203 shares of the financial services provider’s stock valued at $40,000 after buying an additional 170 shares during the last quarter. Institutional investors own 87.75% of the company’s stock.

Insiders Place Their Bets

In related news, Director Martin J. Gepsman sold 400 shares of CME Group stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $222.92, for a total transaction of $89,168.00. Following the completion of the sale, the director now owns 25,067 shares in the company, valued at $5,587,935.64. This trade represents a 1.57 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Timothy Francis Mccourt sold 1,374 shares of the business’s stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $227.12, for a total transaction of $312,062.88. Following the completion of the sale, the insider now directly owns 7,275 shares of the company’s stock, valued at approximately $1,652,298. This trade represents a 15.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 15,621 shares of company stock worth $3,441,063 over the last quarter. Company insiders own 0.30% of the company’s stock.

CME Group Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 27th. Shareholders of record on Monday, December 9th will be given a $1.15 dividend. This represents a $4.60 annualized dividend and a yield of 2.04%. The ex-dividend date of this dividend is Monday, December 9th. CME Group’s dividend payout ratio (DPR) is presently 48.37%.

About CME Group

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.